Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2164-2168

  Hainsworth, John D ^a   Burris III, Howard A ^a   Erland, Joan B ^a   Thomas, Melodie ^a   Greco, F Anthony ^a  

^a CENTENNIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PACLITAXEL;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CARCINOMA; CLINICAL ARTICLE; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERANCE; FATIGUE; HUMAN; LEUKOPENIA; MYALGIA; PRIORITY JOURNAL;

EID: 0031800526     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2164     Document Type: Article

References (14)

1. Ravdin PM, Burns HA, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
2. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoiplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
3. Dreyfuss AI, Clark JR, Morris CM, et al: Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14:1672-1678, 1996
4. Fossella FV, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 12:1238-1244, 1994
5. Francis P, Schneider J, Hann L, et al: Phase II trial of docetaxel in patients with platinum refractory advanced ovarian cancer. J Clin Oncol 12:2301-2308, 1994
6. Gueritte-Voegelein F, Guenard D, Lavelle F, et al: Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 24:992-998, 1991
7. Belani CP, Hadeed V, Ramanathan R, et al: Docetaxel and carboplatin: A phase I and pharmacokinetic trial for advanced non-hematologic malignancies. Proc Am Soc Clin Oncol 16:220A, 1997 (abstr)
8. Trudeau ME, Eisenhauer EA, Higgins BP, et al: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 14:422-428, 1996
9. Dieras V, Fumoleau P, Chevallier B, et al: Second EORTC-Clinical Screening Group phase II trial of Taxotere (docetaxel) as first line chemotherapy in advanced breast cancer. Proc Am Soc Clin Oncol 13:78, 1994 (abstr)
10. Fennelly D, Aghajanian C, Shapiro F, et al: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187-192, 1997
11. Seidman AD, Murphy B, Hudis C, et al: Activity of Taxol by weekly 1-hour infusion in patients with metastatic breast cancer: A phase II and pharmacologic study. Proc Am Soc Clin Oncol 16:148A, 1997 (abstr)
12. Ackerley W, Giantz M, Choy H, et al: Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 16:153-158, 1998
13. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 13:1860-1870, 1995
14. Kearns CM, Belani CP, Erkmen K, et al: Reduced platelet toxicity with combination carboplatin and paclitaxel: Pharmacodynamic modulation of carboplatin-associated thrombocytopenia. Proc Am Soc Clin Oncol 14:170, 1995 (abstr)